Recent Analysts’ Ratings Updates for Organogenesis (ORGO)

A number of firms have modified their ratings and price targets on shares of Organogenesis (NASDAQ: ORGO) recently:

• 12/15/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Organogenesis had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
• 12/8/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Organogenesis had its price target raised by analysts at BTIG Research from $7.00 to $9.00. They now have a “buy” rating on the stock.
• 11/19/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Organogenesis had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Organogenesis was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.

Insider Buying and Selling

In other Organogenesis news, Director Glenn H. Nussdorf sold 187,957 shares of Organogenesis stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $5.29, for a total transaction of $994,292.53. Following the sale, the director owned 2,765,591 shares in the company, valued at $14,629,976.39. The trade was a 6.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 300,000 shares of company stock valued at $1,592,120 over the last three months. 33.00% of the stock is owned by company insiders.

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.